Preserving Prosperity By Extending Health Span Of Society One Patient At A Time

Nee Soon Clinic
7 Oct 2026
Injectable Moisturiser (HA Microdroplets) vs Polynucleotide Injection: Which Is Better for Skin Quality in Singapore?
Patients comparing injectable skin treatments often ask whether they should choose a hyaluronic acid treatment designed to improve hydration and surface smoothness, or a polynucleotide treatment intended to support skin quality through a different biological pathway.
The short answer is that they are not interchangeable. The hyaluronic acid option is an intradermal HA gel placed as multiple small microdroplets to improve attributes such as hydration, smoothness and fine lines. The polynucleotide option is a purified polynucleotide injectable made from DNA-derived chains, used with the intention of improving skin quality through tissue-supportive and remodelling mechanisms. The choice should begin with the problem being treated, not with whichever product is currently more popular.

If your main concern is dehydration, roughness or loss of surface smoothness, read our main guide to injectable moisturiser treatment in Singapore. This article focuses specifically on how the two injectable categories differ, what the published evidence shows and where uncertainty still remains.
Short answer: Hyaluronic acid microdroplets have direct clinical evidence for improving cheek smoothness, fine lines and hydration. Polynucleotide injections have emerging evidence for fine lines, texture, elasticity and broader skin-quality improvement, but the evidence base is smaller and more heterogeneous. Neither treatment is universally better — the right choice starts with the skin problem, not the product name.
What Is the Main Difference?
The main difference is the material being injected and therefore the treatment objective. Both treatments involve multiple small injections into the skin, but they are not simply two brands doing the same thing.
Intradermal hyaluronic acid for skin quality
The hyaluronic acid option belongs to the VYC-12L family of injectable HA gels. Hyaluronic acid is a naturally occurring glycosaminoglycan with a strong ability to bind water. In this form, the product is placed within the dermis in very small amounts distributed across a treatment area. It is not used like a structural cheek, chin or lip filler whose purpose is to create projection or replace deeper volume.
The clinical target is skin quality. Published VYC-12L studies have assessed cheek smoothness, fine lines, skin roughness and instrument-measured hydration. In a multicentre randomised study involving 202 participants, 131 received treatment and 71 were untreated controls.
At one month, 57.9% of treated participants met the study definition of a cheek-smoothness responder compared with 4.5% of controls, while 58.3% met the fine-line responder definition compared with 5.4% of controls. These were study-specific definitions and should not be interpreted as a guaranteed individual success rate.

Purified polynucleotides
The polynucleotide option is based on purified polynucleotides: long DNA-derived chains obtained from fish sources, commonly described in the literature as salmon-derived. These are not hyaluronic acid molecules.
Polynucleotide products are often described as regenerative injectables because laboratory and clinical research suggests effects on the tissue environment, fibroblast activity, extracellular-matrix behaviour, hydration and repair signalling.
The word regenerative needs to be used carefully. Some proposed mechanisms are supported more strongly by laboratory and animal work than by large human trials. A medically accurate description is that polynucleotides are used with the aim of improving skin quality and supporting tissue remodelling, with a growing but still developing clinical evidence base.
HA Microdroplets and Polynucleotides at a Glance
Feature | Injectable moisturiser (HA microdroplets) | Polynucleotide (PN) injection |
Material | Cross-linked hyaluronic acid gel | Purified polynucleotides |
Main concept | Hydration, smoothness and fine-line improvement | Skin-quality support and tissue remodelling |
Volume effect | Not intended as a structural volumising filler | Not intended as conventional structural filler |
Injection pattern | Multiple small intradermal microdroplets | Multiple small intradermal injections |
Evidence | Several prospective studies including a randomised multicentre study | Growing evidence; reviews still note heterogeneity and limited high-quality trials |
Typical focus | Dehydration, roughness, fine lines | Fine lines, texture, elasticity, delicate skin |
Typical schedule | Initial treatment, review or possible touch-up, later maintenance | Often a short series followed by maintenance |
Common downtime | Bumps, redness, swelling, tenderness, bruising | Papules, redness, swelling, tenderness, bruising |
How Hyaluronic Acid Microdroplets Work
Hyaluronic acid is naturally present in the extracellular matrix of the skin. It binds water and contributes to hydration, viscoelasticity and the physical environment surrounding skin cells. With age and cumulative environmental exposure, skin becomes drier, less elastic and less able to maintain a smooth surface. An intradermal HA gel places a water-attracting material within the skin itself.
This is different from simply applying a moisturiser. Topical moisturisers mainly act at the skin barrier and reduce water loss from the surface. An injectable HA treatment is placed below the surface. It is also different from a conventional volumising dermal filler: the microdroplets are spread across an area to improve skin quality rather than concentrated in a deeper pocket to change facial structure.
A prospective study of 131 subjects treated with VYC-12 reported significant improvement in instrument-measured hydration through nine months. Investigator-rated roughness improved most strongly in the early months and declined over time. This illustrates an important point: hydration and visible texture are related but are not identical outcomes, and maintenance is eventually required.
How Polynucleotide Injections Work
Polynucleotides are chains of nucleotides, the building blocks of DNA.
Aesthetic PN products use highly purified DNA fragments formulated for injection into tissue. Proposed effects include creating a hydrophilic matrix, influencing inflammatory and repair signalling, and supporting fibroblast and extracellular-matrix activity. Some related PDRN literature also discusses adenosine A2A-receptor signalling, although PN and PDRN should not automatically be treated as identical terms or assumed to have identical pharmacology.
The clinical evidence is increasing but still limited. A 2024 systematic review of nine studies involving 219 patients concluded that PN injections showed promising improvements in wrinkles, texture and elasticity, while also emphasising that the included studies were of low to moderate quality and that injection techniques varied substantially. A 2026 systematic review of randomised trials across skin rejuvenation, scar prevention and wound healing identified only seven randomised studies with 183 participants in total. There is real clinical evidence, but the evidence base is much smaller than the popularity of the treatment may suggest.
There is also product-specific evidence. An earlier randomised matched-pair clinical trial involving 72 patients compared a polynucleotide injectable with a non-cross-linked hyaluronic acid product for crow's feet. Three treatments were performed at two-week intervals. The study found no statistically significant difference between the two treatments on its primary and secondary clinical efficacy outcomes, although laboratory and skin-property measurements suggested differences in elasticity, collagen composition, surface roughness and wrinkle depth. This supports the idea that both approaches may improve skin quality while acting differently; it does not establish that one is universally superior.
Which Is Better for Hydration?
If hydration is the dominant problem, the evidence for VYC-12L is particularly direct because hydration has been measured objectively in clinical studies. In the 2019 prospective study, skin hydration remained significantly improved from baseline through nine months. The randomised 2023 trial also included hydration among its measured skin-quality outcomes.
Polynucleotides may also improve hydration. PN molecules are hydrophilic and several clinical reports describe improvements in hydration or overall skin quality. However, the literature is less standardised: products, concentrations, injection techniques, anatomical areas and outcome measures vary. A patient whose main complaint is dehydrated, rough skin may therefore be assessed differently from someone whose main concern is thin, crepey periocular skin or broader textural change.
For patients specifically researching HA microdroplet hydration, our detailed guide to injectable moisturiser treatment in Singapore explains how intradermal hyaluronic acid differs from volumising filler and topical skincare.
Which Is Better for Fine Lines, Texture and Thin Skin?
Fine lines are not all the same. A superficial line caused partly by dehydration and reduced surface smoothness is different from a dynamic expression line, a deeply etched wrinkle, a volume-related fold or very thin lower-eyelid skin. Treatment selection should therefore be anatomical and diagnostic rather than based only on age.
Fine lines linked to dryness and rough texture
Hyaluronic acid microdroplets have specific clinical data showing improvement in fine-line scores and skin smoothness. In the 2023 VYC-12L randomised study, the month-one fine-line responder rate was 58.3% in treated participants compared with 5.4% in untreated controls. These results were based on a validated study scale and should not be translated into an individual percentage chance of success, but they demonstrate that fine lines were a measured endpoint rather than a purely subjective claim.
Thin, delicate or periocular skin
Polynucleotides are frequently selected by clinicians for thinner or more delicate areas, particularly around the eyes, because the therapeutic goal is skin quality rather than conventional volume replacement. A survey of 235 Korean board-certified dermatologists found that common PN indications included cheek fine lines, infraorbital and periorbital fine lines, uneven texture and dry skin. This was a practice-pattern survey rather than a randomised trial, so it tells us how experienced clinicians use PN, not that every indication is proven to the same level.
For the under-eye area, anatomy matters enormously. Puffiness, pigment, visible vessels, tear-trough hollowing, laxity and fine lines can all create a tired appearance but require different strategies. An injectable should not be chosen simply because it is marketed as an under-eye treatment.
Acne scars or damaged texture
PN research also extends into acne scarring and wound-repair contexts. Small studies have reported improvements in scar appearance and skin texture, and the 2026 systematic review identified randomised evidence across rejuvenation, postoperative scar prevention and wound healing. However, acne scars are structural defects and often require scar-specific treatment such as subcision, energy-based procedures or other modalities. Polynucleotide injection should not be presented as a universal replacement for established scar treatments.
Treatment Course, Downtime and Maintenance
The treatment burden is another meaningful difference. HA microdroplet treatment has generally been studied as an initial treatment with review and an optional touch-up, followed by later repeat treatment as results diminish. Polynucleotide protocols are more commonly delivered as a series.
In a Korean dermatologist practice survey, three PN sessions spaced approximately four weeks apart was the most commonly reported initial schedule. In the 72-patient polynucleotide crow's-feet trial, treatment was repeated three times at two-week intervals. These examples show why a clinic should not publish one rigid schedule as though it applies to every PN product, concentration, treatment area and patient.
What downtime can look like
Both treatments involve multiple skin injections, so the immediate appearance can include small raised bumps at injection points, redness, swelling, tenderness and occasional bruising. With superficial microdroplet techniques, visible papules may persist for several hours and sometimes into the following day or two. Around thin periocular skin, swelling can be more obvious.
Patients should plan treatment around important events and follow their clinician's aftercare instructions. Persistent severe pain, marked colour change, blistering, progressive swelling, fever or other unexpected symptoms require prompt medical review rather than routine watch-and-wait.
How long do results last?
Duration cannot be reduced to one number because different outcomes fade at different rates. In a prospective VYC-12 study, investigator-rated roughness improvements declined between months one and six, while instrument-measured hydration remained significantly improved through month nine. Repeat treatment restored a high roughness responder rate in that study. This supports maintenance, but it does not mean every patient should be retreated at exactly nine months.
For polynucleotides, published protocols commonly assess results over several months after a course. A 2024 study of 30 Asian subjects receiving three PN-HPT sessions reported improvements in surface quality, firmness, pigmentation and radiance that persisted to six months. That study involved a PN-HPT product rather than one specific brand, so it is supportive evidence for the category rather than a precise durability promise for every patient.
What About Safety?
No injectable treatment is risk-free. Expected short-term effects for both categories include injection-site redness, swelling, tenderness, bruising and temporary bumps. Infection is uncommon when appropriate aseptic technique is used but remains possible whenever the skin barrier is breached.
Hyaluronic acid products have one practical characteristic: HA can be degraded with hyaluronidase when clinically appropriate. This does not eliminate the need for safe injection technique, because vascular complications from injectable materials can be serious and time-sensitive. Polynucleotides are not reversed with hyaluronidase.
Published PN studies generally report mild and transient adverse events, but systematic reviews emphasise the small evidence base. The absence of a rare complication in a small study does not prove that it cannot occur. Product quality, sterility, anatomy, injection depth and clinician training remain important.
Who May Not Be Suitable?
Suitability depends on medical history, the specific product and the treatment area. A doctor may postpone or avoid elective injection when there is active infection, significant inflammation at the treatment site, certain uncontrolled medical conditions, or when the expected benefit does not match the patient's concern.
Pregnancy and breastfeeding, allergy history, previous injectable complications, anticoagulant or antiplatelet use, autoimmune disease, immunosuppression and fish-related allergy concerns may require individual discussion. Patients should not stop prescribed medication in order to undergo an aesthetic procedure unless the prescribing clinician advises it.
Can the Two Be Combined?
Potentially, but more treatment is not automatically better treatment. Because HA microdroplets and polynucleotides have different treatment concepts, a clinician may sometimes sequence different modalities when a patient has more than one skin-quality problem. Dehydration and roughness, for example, can coexist with delicate periocular texture, pigmentation or volume loss.
A rational plan identifies the dominant problem first, chooses the intervention most likely to address it and then reviews the response before adding another treatment. This approach also makes it easier to understand which treatment produced benefit or side effects.
Which Treatment Gives More Glow?
Glow is not a single biological endpoint. Skin appears more luminous when its surface is smoother, hydration is adequate, pigmentation is more even and underlying circulation gives healthy colour. Both HA and PN treatments may influence some of these components, but through different routes. A patient with dehydration-driven dullness may respond differently from someone whose main issue is pigmentation, photodamage or rough keratinisation.
Before-and-after photography should also be interpreted cautiously. Lighting, camera exposure, makeup, expression and temporary post-injection swelling can all alter appearance. Objective scales and instrument measurements are useful in trials because they reduce, although do not completely remove, this subjectivity.
How a Doctor Chooses Between Them
A good consultation should begin with the skin rather than the brand. The doctor may assess hydration, surface roughness, pore visibility, fine-line pattern, elasticity, skin thickness, pigmentation, vascular redness, underlying volume loss and the anatomical area being treated. They should also ask what bothers the patient most and what level of downtime or repeated treatment the patient is willing to accept.
In practical terms, HA microdroplets may be attractive when the treatment goal is clearly hydration and smoother skin. PN treatment may be considered when the clinical focus is broader skin-quality support, fine lines or delicate tissue. Some patients may be candidates for either approach. Others may need neither because the dominant issue is facial volume loss, dynamic muscle movement, pigment, active acne, scarring or another condition that requires a different treatment.
That is the most useful way to think about this comparison: not as a contest between two popular injectables, but as a diagnostic decision about which mechanism best fits the skin problem in front of the doctor.
Frequently Asked Questions
Is the HA microdroplet treatment the same as a dermal filler?
It contains cross-linked hyaluronic acid, so it belongs to the broader HA injectable family, but its intended use and injection pattern differ from a conventional volumising filler. It is placed as small intradermal microdroplets to improve skin quality rather than as a deeper structural deposit intended to create projection or contour.
Is the polynucleotide injection a hyaluronic acid skin booster?
No. It is based on purified polynucleotides rather than hyaluronic acid. Both are often grouped under the broad term “skin booster”, but that label can hide important differences in composition, mechanism, treatment schedule and evidence.
Which hurts more?
Both involve multiple injections, so discomfort depends on technique, treatment area, injection depth, formulation and individual pain tolerance. Thin areas such as the lower eyelids are generally felt more. Topical anaesthetic and other comfort measures may be used where appropriate.
Which has more downtime?
Both can produce temporary bumps, redness, swelling and bruising. The exact appearance depends heavily on the area and technique. Polynucleotide treatments are often delivered through many small papular injections, so visible bumps can be part of the immediate post-treatment appearance. HA microdroplets can do the same.
Can the polynucleotide injection replace dermal filler?
Not when the main problem is structural volume loss that requires projection or support. Polynucleotides are primarily used for skin quality rather than conventional facial volumisation. Likewise, the HA microdroplet treatment is not intended to replace a structural filler when contour restoration is the actual goal.
Can the HA microdroplet treatment replace skincare?
No. Injectable HA does not replace sunscreen, moisturiser, appropriate cleansing or treatment of conditions such as acne, eczema or pigment disorders. It can address a specific component of skin quality, while everyday skin care remains important.
How many sessions are needed?
HA microdroplet (VYC-12L) treatment has been studied as an initial treatment with an optional touch-up and later maintenance. PN protocols vary, but a three-session initial series is commonly reported in the literature and in Korean dermatologist practice patterns. The schedule should be tailored to the product, anatomy, response and treatment goal.
Selected Clinical References
1. Alexiades M, Palm MD, Kaufman-Janette J, et al. A randomized, multicenter, evaluator-blind study to evaluate the safety and effectiveness of VYC-12L treatment for skin quality improvements. Dermatol Surg. 2023;49(7):682-688.
2. Niforos F, Ogilvie P, Cavallini M, et al. VYC-12 injectable gel is safe and effective for improvement of facial skin topography: a prospective study. Clin Cosmet Investig Dermatol. 2019;12:791-798.
3. Lee KWA, Chan KWL, Lee A, et al. Polynucleotides in aesthetic medicine: a review of current practices and perceived effectiveness. Int J Mol Sci. 2024;25(15):8224.
4. The effectiveness of polynucleotides in esthetic medicine: a systematic review. 2024.
5. Alhussain AM, et al. Polynucleotides and polydeoxyribonucleotides for skin rejuvenation, postoperative scar prevention, and wound healing: a systematic review of randomized clinical trials. Cureus. 2026;18(7):e112403.
6. A phase III randomized matched-pairs trial comparing a polynucleotide injectable and a hyaluronic acid product for crow's feet.
7. A survey on the cosmetic use of injectable polynucleotide: the pattern of practice among Korean dermatologists.
8. Polynucleotides HPT for Asian skin regeneration and rejuvenation.
Official websites: https://www.skinvivebyjuvederm.com/ and https://www.rejurancosmetics.com/
More on skin boosters
Skin Boosters in Singapore: Types, Results and Prices
Injectable Moisturiser Results, Duration and Price
Swelling and Aftercare After a Skin Booster Injection
Disclaimer:The information provided in this article is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. The content is not intended to be a comprehensive source of information and should not be relied upon as such. Reliance on any information provided in this article is solely at your own risk. The authors and the publisher do not endorse or recommend any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned in the article. Any reliance on the information in this article is solely at the reader's own risk.
779 Yishun Ave 2, #01-1547, Singapore 760779
Tel: 6721 9796

